10 months ago
61 Kindeva Drug Delivery, a specialist in drug-device combination products, has acquired Summit Biosciences, an intranasal drug-delivery contract development and manufacturing organisation (CDMO), from its founding family shareholders.
Established in 2009, Summit has a track record of innovation in the unit dose nasal spray market. The acquisition of Summit enhances Kindeva’s existing drug-delivery capabilities by adding a new drug-delivery platform, expanding Kindeva’s ability to serve biopharma customers across complex drug-device combination products (pulmonary, injectable, transdermal, and nasal).
Kindeva CEO Milton Boyer, said: “Nasal drug delivery is becoming a preferred dosage format for a growing number of indications, as it allows users to non-invasively administer medications in an acute or emergency setting. Summit brings a differentiated understanding of how to effectively formulate drugs for nasal delivery and the capability to manufacture them at commercial scale. This addition not only fits Kindeva’s ambition to be a global leader in the drug-device combination products CDMO market, but also expands the toolbox we can offer our customers to help improve patient outcomes and experience of care globally.”
Departing Summit chairman and CEO Richard D. Cohen added: “Joining Kindeva strengthens our ability to deliver best-in-class nasal product development and manufacturing. Under Kindeva’s leadership, our dedicated and talented workforce will further drive our founder’s vision of increasing the availability of nasal drug-delivery options.”
Summit’s 55,000-square-foot cGMP facility in Lexington, Kentucky, adds to Kindeva’s global manufacturing footprint of nine development and manufacturing facilities across the U.S. and U.K. The facility is approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and features specialised laboratories and integrated manufacturing operations with a track record in bringing intranasal medicines to market.
